MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Mutua de Terrassa](/img/noimage_org.png)
Mutua de Terrassa
Terrassa, EspañaPublicaciones en colaboración con investigadores/as de Mutua de Terrassa (8)
2022
2019
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
2014
-
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
BMC Cancer, Vol. 14, Núm. 1
-
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer
Oncology Research, Vol. 21, Núm. 4, pp. 181-191
2011
2010
-
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer
Chemotherapy, Vol. 56, Núm. 2, pp. 142-146
2005
-
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
European Journal of Cancer, Vol. 41, Núm. 15, pp. 2241-2249